Drugs & Targets Novartis, MEI Pharma. Receive Breakthrough Therapy Designations September 22, 2016Vol.39 No.08
Study Confirms Association Between RFA Burn Time, OS In Patients Receiving ThermoDox September 22, 2016Vol.39 No.08
Two-drug Immunotherapy May Produce Better Survival in Advanced Melanoma September 22, 2016Vol.39 No.08
Abemaciclib Phase III Trial Continues After Interim Efficacy Criteria Not Met September 22, 2016Vol.39 No.08
Tecentriq Demonstrates Increase In Overall NSCLC Survival in Phase III Study September 22, 2016Vol.39 No.08
